Bristol Myers' $9 Celgene CVR is teetering on the brink of disaster as the FDA delays the liso-cel application yet again

Bristol Myers' $9 Celgene CVR is teetering on the brink of disaster as the FDA delays the liso-cel application yet again

Source: 
Endpoints
snippet: 

The CVR ($BMYRT) tied to Bristol Myers Squibb’s big Celgene buyout took one more step right to the brink Monday afternoon.